At the ongoing trial concerning the "Dok-1 Max" syrup, allegedly responsible for the tragic deaths of 65 children in Uzbekistan, new revelations emerged on September 15 as the former head of the registration department, Sh.Sh., provided crucial testimony. During his questioning, he disclosed that a certificate for another Indian drug was issued for inspection, following the instructions of an unnamed leader.
The defendant, Sh.Sh., who previously served as the head of the registration department at the "State Center for Expertise and Standardization of Medicines, Medical Devices, and Medical Equipment," explained,
"The leader, M.N., instructed his deputy, whose name I cannot recall precisely. I then sought confirmation from the first deputy, A.A., who was passing by in the corridor. Subsequently, I conveyed to the deputy leader that no action could proceed without a formal protocol. Later, the council's secretary, U.T., brought the certificate with his signature. This information is documented in the ongoing investigation."
According to court records, the expert council examined 400 drugs produced by India's Marion Biotech Pvt. Ltd., including the drug "Kuraraks-200."
The defendant further revealed that the usual procedure entails issuing a certificate to a drug subject to inspection only after a comprehensive examination and approval by the Council. However, in the case of "Kuraraks-200," despite being designated for inspection, the certificate was issued without undergoing the necessary examination process.
Investigative documents showed that, Marion Biotech Pvt. Ltd.'s "Kuraraks-200, 400" was never inspected at the manufacturing facility, contrary to established regulations, and was registered after a delay of 34-55 days.
In previous statements, the defendant had vehemently denied allegations of receiving a bribe of 33,000 units from an Indian entity in exchange for registering the drug "Kuraraks-200, 400." During the trial, he reiterated his denial of these charges.
The trial surrounding the "Dok-1 Max" syrup remains a matter of significant concern, as it continues to uncover irregularities and potential misconduct in the registration and approval process of pharmaceutical products, particularly those related to the tragic deaths of numerous children in Uzbekistan.
Earlier Daryo reported that in a recent court hearing, defendant G.B. made notable disclosures, revealing that Indian Marion Biotech Pvt. Ltd. officials had requested registration for four more drugs containing harmful substances akin to those present in the infamous "Dok-1 Max" syrup.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)